Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cereno Scientific (XSAT: CRNO B) today announced that Nick Oakes has been appointed as Head of Preclinical Development. The appointment brings significant experience within preclinical research and development in cardiovascular disease, a key factor for the success of Cereno's continued pipeline development.
"I am excited to welcome Nick to Cereno and believe he will be a strong complement to our Executive Management Team. His long-standing experience within preclinical drug development will be instrumental as our preclinical programs continue advancing towards Phase I IND submission," says Sten R. Sörensen, CEO at Cereno Scientific.
In his role as Head of Preclinical Development, Nick will assume global management responsibilities for all Cereno's discovery and preclinical activities including strategy definition, programs implementation, and delivery of key milestones. Nick has a PhD in cardiovascular and metabolic research from the University of New South Wales, Sydney, Australia. He has more than 20 years of experience working in the pharmaceutical industry with both efficacy and safety related aspects of preclinical research to discover and develop new effective and safe medicines in metabolic, cardiovascular and renal disease areas.
Nick takes over the role as Head of Preclinical Development from Fredrik Lehmann who has held the position during an interim period. Nick will be a member of Cereno's Executive Management Team and report to the CEO. He will assume his position no later than August.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1's safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.